Cumberland Pharmaceuticals announced updated positive results from its Phase 2 FIGHT DMD trial of ifetroban, an oral therapy targeting heart disease in Duchenne muscular dystrophy (DMD) patients. The trial showed ifetroban improves heart function by increasing left ventricular ejection fraction and reducing markers of heart muscle damage, with sustained benefits and a good safety profile over 36 months. This is significant as there are currently no approved treatments specifically for DMD-related cardiomyopathy, the leading cause of death in these patients. Cumberland plans further long-term analyses and supportive studies to advance ifetroban's development.
Peec AI has assembled a team of SEO experts and AI researchers to understand how AI platforms like ChatGPT, Perplexity, and Google's AI Mode select and recommend brands. This team uses reverse-engineering and experimental analysis to decode the opaqu...
The global Laboratory Information Management Systems (LIMS) market is projected to grow from $2.88 billion in 2025 to $5.19 billion by 2030, at a CAGR of 12.5%. Growth is fueled by rising demand for laboratory automation, regulatory compliance, and d...
The global protein ingredients market is projected to grow from $83.14 billion in 2026 to $121.53 billion by 2031, at a CAGR of 7.9%. Growth is fueled by rising consumer demand for functional and high-protein foods, increased awareness of protein's h...
Cate & Chloe is participating in Walmart's Summer Deals Event from June 22 to June 28, offering its Eden 18k White Gold Plated Crystal Stud Earrings at a discounted price of $16.99, down from $77. This sale highlights the brand's focus on affordable ...
UBS Group AG has increased its stake in Bang & Olufsen A/S to 5.07% of the total share capital and voting rights as of June 23, 2026, holding 7,473,135 shares. This change follows a previous holding below 5% on June 22, 2026, marking UBS as a major s...
